U.S. and E.U. data suggest favorable outcomes to alternative transplants for hematologic cancers and genetic blood diseases.
Saranas closes funding round, previously they have raised around $8 million.
Adesis Inc., purchased its New Castle, Delaware building, to expand its custom organic synthesis, research & development, and specialty manufacturing capabilities.
BioHouston announced that Ann Tanabe has been named the organization’s chief executive officer. Ann previously served as BioHouston’s chief operating officer, and is replacing current CEO Jacqueline Northcut, who is departing to pursue other opportunities.
The sky threatened thunderstorms but the only jolt came from the spices at BioHouston’s latest annual chili cookoff.
Approval of the IND application is required in order for ESSA to commence human testing of EPI-506 in the US.
This agreement represents an expansion of the licensing agreement previously entered into by Ipsen and Lexicon in October 2014.
The B round was led by Switzerland-based Pamoja Capital and GPG Ventures in Dallas.